Market Place
Sourcing Support
Avadel Pharma to Present at Jefferies London Healthcare Conf.
13 Nov 2024 //
GLOBENEWSWIRE
Avadel Pharmaceuticals to Report Q3 2024 Results on Nov 12
04 Nov 2024 //
GLOBENEWSWIRE
Avadel Pharmaceuticals Wins Administrative Procedure Act Ruling
31 Oct 2024 //
GLOBENEWSWIRE
Avadel And Nference Publish Sleep Advances Real-World Data
24 Oct 2024 //
GLOBENEWSWIRE
Avadel Pharmaceuticals Gets FDA Approval For LUMRYZ™ Suspension
17 Oct 2024 //
GLOBENEWSWIRE
US FDA expands use of Avadel`s sleep disorder drug to ages 7 and up
17 Oct 2024 //
REUTERS
Avadel Pharma Publishes Data On LUMRYZ Efficacy In Narcolepsy
25 Sep 2024 //
GLOBENEWSWIRE
Avadel Pharma says its sleep disorder drug remains under FDA review
12 Sep 2024 //
REUTERS
Avadel Publishes RESTORE Data Favoring Once-Nightly LUMRYZ Dosing
03 Sep 2024 //
GLOBENEWSWIRE
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
28 Aug 2024 //
GLOBENEWSWIRE
Avadel`s LUMRYZ Data On Weight Loss In Narcolepsy Published
20 Aug 2024 //
GLOBENEWSWIRE
Avadel Pharmaceuticals Reports Q2 2024 Results And Corporate Update
08 Aug 2024 //
GLOBENEWSWIRE
Avadel To Report Q2 2024 Results On August 8
01 Aug 2024 //
GLOBENEWSWIRE
Avadel Doses First Patient In Phase 3 LUMRYZ™ Trial For Hypersomnia
31 Jul 2024 //
GLOBENEWSWIRE
Avadel Pharmaceuticals to Join Russell 3000® Index
27 Jun 2024 //
GLOBENEWSWIRE
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
30 May 2024 //
GLOBENEWSWIRE
Avadel Shares LUMRYZ Data At SLEEP 2024
22 May 2024 //
GLOBENEWSWIRE
Avadel Pharmaceuticals Appoints Naseem Amin, M.D. to its Board of Directors
21 May 2024 //
GLOBENEWSWIRE
Avadel Q1 2024 Update, Financial Results
08 May 2024 //
GLOBENEWSWIRE
Avadel Q1 2024 Results, Corporate Update On May 8
01 May 2024 //
GLOBENEWSWIRE
Avadel Pharmaceuticals to Present at the 23rd Annual Healthcare Conference
01 Apr 2024 //
GLOBENEWSWIRE
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
05 Mar 2024 //
GLOBENEWSWIRE
Avadel Reports Fourth Quarter and Full Year 2023 Financial Results
04 Mar 2024 //
GLOBENEWSWIRE
Avadel Pharmaceuticals Issues Statement On Patent Litigation
04 Mar 2024 //
GLOBENEWSWIRE
Avadel Pharma to Report Fourth Quarter and Full Year 2023 Financial Results
26 Feb 2024 //
GLOBENEWSWIRE
Avadel Pharmaceuticals to Present at the Oppenheimer 34th Annual Conference
07 Feb 2024 //
GLOBENEWSWIRE
Avadel Pharmaceuticals Announces Strong LUMRYZ Launch Performance
08 Jan 2024 //
GLOBENEWSWIRE
Avadel Provides Corporate Update & Reports Third Quarter 2023 Financial Results
08 Nov 2023 //
GLOBENEWSWIRE
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
07 Nov 2023 //
GLOBENEWSWIRE
Avadel Pharmaceuticals to Report Third Quarter Financial Results on November 8
30 Oct 2023 //
GLOBENEWSWIRE
Avadel Pharmaceuticals Announces Data Supporting Clinical Profile for LUMRYZ
20 Oct 2023 //
GLOBENEWSWIRE
Avadel Pharmaceuticals to Present at the Jefferies Biotech CNS/Neuro Summit
05 Oct 2023 //
GLOBENEWSWIRE
Avadel Provides Corporate Update & Reports Second Quarter 2023 Financial Results
09 Aug 2023 //
GLOBENEWSWIRE
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
03 Aug 2023 //
GLOBENEWSWIRE
Avadel to Report Second Quarter Financial Results on August 9
02 Aug 2023 //
GLOBENEWSWIRE
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
20 Jul 2023 //
GLOBENEWSWIRE
Avadel launches quick start to narcolepsy drug’s marketing
10 Jul 2023 //
ENDPTS
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
06 Jul 2023 //
GLOBENEWSWIRE
FDA faces lawsuit from Jazz after approval of Avadel`s sleep aid
24 Jun 2023 //
FIERCE PHARMA
Avadel to Host Commercial Day on June 29 for LUMRYZ (sodium oxybate)
22 Jun 2023 //
GLOBENEWSWIRE
Avadel Sponsors Academy of Sleep Medicine Foundation™s 2023 Research Forum
14 Jun 2023 //
GLOBENEWSWIRE
Avadel Announces Publication of Study Data in Advances in Therapy
13 Jun 2023 //
GLOBENEWSWIRE
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
06 Jun 2023 //
GLOBENEWSWIRE
Avadel Pharmaceuticals Announces U.S. Commercial Launch of LUMRYZ
05 Jun 2023 //
GLOBENEWSWIRE
Avadel Pharmaceuticals to Present at the Jefferies Healthcare Conference
01 Jun 2023 //
GLOBENEWSWIRE
Avadel Announces Data Supporting Clinical Profile for LUMRYZ at SLEEP 2023
31 May 2023 //
GLOBENEWSWIRE
Avadel Pharmaceuticals Provides Corporate Update and Reports 1Q 2023 FYR
04 May 2023 //
GLOBENEWSWIRE
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
03 May 2023 //
GLOBENEWSWIRE
FDA endorses Avadel`s Lumryz, a major threat to Jazz`s Xyrem
03 May 2023 //
ENDPTS
Avadel Pharmaceuticals Lumryz (sodium oxybate) Receives Approval in the U.S
01 May 2023 //
FDA
Avadel Announces Final FDA Approval of sodium oxybate
01 May 2023 //
GLOBENEWSWIRE
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
20 Apr 2023 //
GLOBENEWSWIRE
Avadel Pharma to Present at the 22nd Annual Needham Healthcare Conference
10 Apr 2023 //
GLOBENEWSWIRE
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
03 Apr 2023 //
GLOBENEWSWIRE
Avadel Pharma Reports Fourth Quarter and Full Year 2022 Financial Results
30 Mar 2023 //
PRESS RELEASE
Avadel Reports 4Q and Full Year 2022 Financial Results
30 Mar 2023 //
GLOBENEWSWIRE
Avadel Enters into Royalty Agreement with RTW Investments for up to $75 Million
29 Mar 2023 //
GLOBENEWSWIRE
Avadel Announces Proposed Underwritten Public Offering of ADSs
29 Mar 2023 //
GLOBENEWSWIRE
Avadel Announces Pricing of Public Offering of ADSs & Series B Preferred Shares
29 Mar 2023 //
GLOBENEWSWIRE
Avadel to Report Fourth Quarter and Full Year 2022 Financial Results on March 30
29 Mar 2023 //
GLOBENEWSWIRE
